• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Watchdog report: Pharma may not be addressing corruption risks

Watchdog report: Pharma may not be addressing corruption risks

June 6, 2016
CenterWatch Staff

The global pharmaceutical sector is wide open to corruption abuse, with both governments and companies failing to properly address corruption risks, according to new research from Transparency International (TI) Pharmaceuticals & Healthcare Program.

As of the beginning of 2016, one in 10 corruption investigations by U.S. authorities involve pharmaceutical companies, significantly higher than the banking sector. Despite the obvious risk, firms are entrusted with a large degree of autonomy, without proper governmental oversight.

The pharmaceutical sector has been largely unchecked for corruption allowing it to develop into one that has allowed profits to be prioritized at the expense of patients’ health.

Sophie Peresson, director, Transparency International Pharmaceuticals & Healthcare Program, said, “The effects of corruption in the pharmaceutical sector and health sector are stark, where it can literally be a matter of life and death. It is shocking that despite scandal after scandal involving pharma companies still policy makers simply are not taking seriously the corrosive effect of corruption. The red flags are being ignored. Governments and pharma companies must recognize their responsibility in fighting corruption and stop turning a blind eye.”

Transparency International’s research found measures to combat corruption inadequate across the following areas:

  • Research and development—raw data from research is publicly available in only a handful of countries.
  • Marketing—Nearly half of investigated (as of January 1, 2016) health sector corruption cases relate to sales and marketing.
  • Manufacturing—Severe lack of enforced regulation to prevent circumnavigation of manufacturing standards through bribery and corruption.
  • Distribution—Many countries have little or no safeguards against vital medicines simply disappearing during the distribution process.

The Transparency International Pharmaceuticals & Healthcare Program identifies four key challenges to preventing corruption in the pharmaceutical sector:

  • Global institutions, governments and companies not committed to preventing corruption.
  • Lack of knowledge and understanding of corruption by policy and decision makers.
  • Weak national and international legislation and regulation due to underinvestment and a lack of oversight.
  • Unbridled power of companies to influence decisions relating to healthcare.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing